← All companies

URGN

UroGen Pharma Ltd.

URGN Nasdaq Pharmaceutical Preparations EDGAR ↗

$38.59

+0.35 +0.92%

Key statistics

from XBRL data in SEC filings

Market cap

$1.88B

Revenue (TTM)

$140M

Net income (TTM)

-$133M

EPS (TTM)

$-2.74

P/E ratio

—

Dividend yield

—

Free cash flow

-$163M

Cash

$110M

Total assets

$254M

Gross margin

89.9%

52-week range

$15.86 – $43.93

Recent SEC filings

40 most recent

Annual, quarterly & current reports

8-K Modified rights of security holders; Director or officer change; Shareholder vote results Jun 23, 2026 8-K Other events Jun 2, 2026 10-Q Quarter ended 2026-03-31 May 6, 2026 8-K Results of operations (earnings release) May 6, 2026 10-K Fiscal year ended 2025-12-31 Mar 2, 2026 8-K Results of operations (earnings release) Mar 2, 2026 8-K Entered a material agreement; Took on a direct financial obligation Mar 2, 2026 10-Q Quarter ended 2025-09-30 Nov 6, 2025 8-K Results of operations (earnings release) Nov 6, 2025 8-K Director or officer change; Shareholder vote results Aug 27, 2025 10-Q Quarter ended 2025-06-30 Aug 7, 2025 8-K Results of operations (earnings release) Aug 7, 2025 8-K Director or officer change Jul 3, 2025 8-K Other events Jun 13, 2025 10-Q Quarter ended 2025-03-31 May 12, 2025 8-K Results of operations (earnings release) May 12, 2025 10-K/A Fiscal year ended 2024-12-31 Apr 30, 2025 10-K Fiscal year ended 2024-12-31 Mar 10, 2025 8-K Results of operations (earnings release) Mar 10, 2025 8-K Entered a material agreement; Unregistered sale of equity Feb 20, 2025 8-K Regulation FD disclosure Jan 14, 2025 10-Q Quarter ended 2024-09-30 Nov 6, 2024 8-K Results of operations (earnings release) Nov 6, 2024 8-K Director or officer change Oct 9, 2024 8-K Took on a direct financial obligation Sep 24, 2024 8-K Director or officer change Sep 13, 2024 8-K Other events Aug 15, 2024 10-Q Quarter ended 2024-06-30 Aug 13, 2024 8-K Results of operations (earnings release) Aug 13, 2024 8-K Director or officer change; Shareholder vote results Aug 8, 2024 8-K Entered a material agreement; Other events Jun 18, 2024 8-K Regulation FD disclosure; Other events Jun 13, 2024 10-Q Quarter ended 2024-03-31 May 13, 2024 8-K Results of operations (earnings release) May 13, 2024 10-K/A Fiscal year ended 2023-12-31 Apr 29, 2024 10-K Fiscal year ended 2023-12-31 Mar 14, 2024 8-K Results of operations (earnings release) Mar 14, 2024 8-K Regulation FD disclosure Mar 4, 2024 8-K Regulation FD disclosure Mar 1, 2024 8-K Regulation FD disclosure Feb 7, 2024